Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Junji Moriya is active.

Publication


Featured researches published by Junji Moriya.


Journal of International Medical Research | 2006

Traditional Chinese Medicine and Kampo: A Review from the Distant past for the Future

F Yu; Takashi Takahashi; Junji Moriya; Ken Kawaura; J Yamakawa; K Kusaka; T Itoh; Shigeto Morimoto; Nobuo Yamaguchi; Tsugiyasu Kanda

Traditional Chinese medicine (TCM) is a complete system of healing that developed in China about 3000 years ago, and includes herbal medicine, acupuncture, moxibustion and massage, etc. In recent decades the use of TCM has become more popular in China and throughout the world. Traditional Japanese medicine has been used for 1500 years and includes Kampo-yaku (herbal medicine), acupuncture and acupressure. Kampo is now widely practised in Japan and is fully integrated into the modern health-care system. Kampo is based on TCM but has been adapted to Japanese culture. In this paper we review the history and characteristics of TCM and traditional Japanese medicine, i.e. the selection of traditional Chinese herbal medicine treatments based on differential diagnosis, and treatment formulations specific for the ‘Sho’ (the patients symptoms at a given moment) of Japanese Kampo - and look at the prospects for these forms of medicine.


Journal of International Medical Research | 2008

A Novel Adipocytokine, Visceral Adipose Tissue-derived Serine Protease Inhibitor (Vaspin), and Obesity

Qian Li; Rui Chen; Junji Moriya; J Yamakawa; Hiroyuki Sumino; Tsugiyasu Kanda; Takashi Takahashi

Visceral adipose tissue-derived serine protease inhibitor (vaspin) is an interesting novel adipocytokine with insulin-sensitizing effects. Some studies have suggested that vaspin could play an important role in the development of obesity and metabolic disorders. The induction of vaspin mRNA expression could represent a compensatory mechanism associated with obesity, severe insulin resistance and type 2 diabetes mellitus, however it is unclear whether a correlation exists between human vaspin serum levels and markers of insulin sensitivity and glucose or lipid metabolism. Vaspin serum concentrations have been shown to be lower in lean subjects and competitive sportsmen with long-term physical training, but they are increased with weight loss associated with a physical training programme. In conclusion, there is at present no clear proof of a causal link between vaspin and visceral fat accumulation, or insulin resistance. This article reviews the role of vaspin in obesity-associated diseases and its potential as a new biomarker for obesity and impaired insulin sensitivity.


Journal of International Medical Research | 2004

Interleukin-6-Induced Reciprocal Expression of SERCA and Natriuretic Peptides mRNA in Cultured Rat Ventricular Myocytes

T Tanaka; Tsugiyasu Kanda; Takashi Takahashi; Seiichiro Saegusa; Junji Moriya; Masahiko Kurabayashi

We investigated the effect of interleukin-6 (IL-6) expression on sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) mRNA levels in cultured rat neonatal ventricular myocytes. IL-6 plays a key role in regulating cardiac hypertrophy and the development of heart failure, and SERCA, ANP and BNP are all cardiac hormones with regulatory properties. Compared with baseline measurements, treatment with 50 U/ml IL-6 significantly decreased SERCA gene expression, but significantly increased ANP and BNP gene expression in the cardiac myocytes. These results suggest that the clinical overproduction of IL-6 in response to infection, autoimmune disease and cancer might be responsible for cardiac hypertrophy. Cardiac hypertrophy may result from the imbalance of both natriuretic peptides and SERCA transciption levels, caused by elevated IL-6 expression.


Evidence-based Complementary and Alternative Medicine | 2010

Traditional Chinese Medicine for Chronic Fatigue Syndrome

Rui Chen; Junji Moriya; Jun-ichi Yamakawa; Takashi Takahashi; Tsugiyasu Kanda

More and more patients have been diagnosed as having chronic fatigue syndrome (CFS) in recent years. Western drug use for this syndrome is often associated with many side-effects and little clinical benefit. As an alternative medicine, traditional Chinese medicine (TCM) has provided some evidences based upon ancient texts and recent studies, not only to offer clinical benefit but also offer insights into their mechanisms of action. It has perceived advantages such as being natural, effective and safe to ameliorate symptoms of CFS such as fatigue, disordered sleep, cognitive handicaps and other complex complaints, although there are some limitations regarding the diagnostic standards and methodology in related clinical or experimental studies. Modern mechanisms of TCM on CFS mainly focus on adjusting immune dysfunction, regulating abnormal activity in the hypothalamic-pituitary-adrenal (HPA) axis and serving as an antioxidant. It is vitally important for the further development to establish standards for ‘zheng’ of CFS, i.e. the different types of CFS pathogenesis in TCM, to perform randomized and controlled trials of TCM on CFS and to make full use of the latest biological, biochemical, molecular and immunological approaches in the experimental design.


Journal of International Medical Research | 2008

Chronic Fatigue Syndrome and the Central Nervous System

Rui Chen; Fengxia Liang; Junji Moriya; Jun-ichi Yamakawa; Hiroyuki Sumino; Tsugiyasu Kanda; Takashi Takahashi

An increasing amount of neuroimaging evidence supports the hypothesis that chronic fatigue syndrome patients have structural or functional abnormalities within the brain. Moreover, some neurotrophic factors, neurotransmitters and cytokines have also been evaluated in order to elucidate the mechanism of abnormal neuropsychic findings in chronic fatigue syndrome. In this review, we suggest that the focal point of chronic fatigue syndrome research should be transferred to the central nervous system.


Neurochemical Research | 2008

Brain Atrophy in a Murine Model of Chronic Fatigue Syndrome and Beneficial Effect of Hochu-ekki-to (TJ-41)

Rui Chen; Junji Moriya; Jun-ichi Yamakawa; Takashi Takahashi; Qian Li; Shigeto Morimoto; Kunimitsu Iwai; Hiroyuki Sumino; Nobuo Yamaguchi; Tsugiyasu Kanda

Brain-derived neurotrophic factor (BDNF) is associated with the main symptoms of chronic fatigue sydrome (CFS) and neuron apoptosis. Nevertheless, no study has been performed directly to explore the relationship between CFS, BDNF and neuron apoptosis. We induced a CFS model by six injections of killed Brucella abortus antigen in BALB/c mice and treated them with Hochu-ekki-to (TJ-41). Daily running activity, body weight (BW), ratio of cerebral weight to BW (CW/BW) and expression levels of BDNF and Bcl-2 mRNA in the hippocampus were determined. The daily activity and CW/BW decreased significantly in the CFS model. BDNF and Bcl-2 mRNA expression levels in the hippocampus were suppressed in the CFS model and TJ-41 treated mice, while no significant difference was found between them. We improved a murine model to investigate the relationship between CFS and brain dysfunction. In this model, reduced daily activity might have been associated with decreased hippocampal BDNF mRNA expression, hippocampal apoptosis and brain atrophy. TJ-41 increased the daily running activity of the model, which was independent of brain recovery.


Journal of International Medical Research | 2004

Effect of the Serotonin Blocker Sarpogrelate on Circulating Interleukin-18 Levels in Patients with Diabetes and Arteriosclerosis Obliterans

J Yamakawa; Takashi Takahashi; Seiichiro Saegusa; Junji Moriya; T Itoh; K Kusaka; Ken Kawaura; Xq Wang; Tsugiyasu Kanda

We aimed to evaluate the effect of treatment with sarpogrelate, a serotonin 2A receptor antagonist, on circulating interleukin (IL)-18 levels in patients with diabetes and arteriosclerosis obliterans. Patients received sarpogrelate (100 mg 3 times daily) for 2 months. We evaluated the degree of cryaesthesia (a feeling of cold in the foot and toes) as the clinical outcome, and measured circulating IL-18, IL-6 and lipid protein concentrations. An improvement in clinical outcome occurred after initiation of sarpogrelate therapy;a significant decrease in IL-18 levels was observed after 2 months of therapy. Levels of IL-6 and lipid proteins, including triglyceride, total cholesterol and high-density lipoprotein cholesterol, were not significantly altered by treatment. Our data suggest that by reducing circulating IL-18 levels, sarpogrelate treatment may contribute to the inhibition of arteriosclerosis obliterans progression in patients with diabetes.


Evidence-based Complementary and Alternative Medicine | 2004

Effect of Hochu-ekki-to (TJ-41), a Japanese Herbal Medicine, on Daily Activity in a Murine Model of Chronic Fatigue Syndrome

Xin Q. Wang; Takashi Takahashi; Shi-jie Zhu; Junji Moriya; Seiichiro Saegusa; Jun-ichi Yamakawa; K Kusaka; Tohru Itoh; Tsugiyasu Kanda

We aimed to evaluate the effect of a Japanese herbal medicine, Hochu-ekki-to (TJ-41), on daily activity in a murine model of chronic fatigue syndrome (CFS). CFS was induced by repeated injection of Brucella abortus (BA) antigen every 2 weeks. TJ-41 was orally administered to mice in a dose of 500 mg/kg/day for 1 week before injecting BA and for 4 weeks thereafter. We evaluated daily running activity in mice receiving TJ-41 as compared with that in untreated mice. Survival of both mouse groups was also monitored during the observation period. Body weight (BW), spleen weight (SW), SW/ BW ratio and expression levels of interleukin-10 (IL-10) mRNA in spleen were determined in both groups at the time of sacrifice. The daily activity was significantly higher in the treated group than in the control. Two mice in the untreated group died 2 days after the second injection of BA, whereas no mice in the group treated with TJ-41 died. The SW and SW/BW ratio were significantly lower in the treated mice than in the control. Suppressed IL-10 mRNA levels were observed in the spleens of the mice treated with TJ-41. Our data suggest that Hochu-ekki-to might possess an inhibitory effect on the marked decrease in running activity following BA injection.


Journal of International Medical Research | 2004

Panic attack symptoms in a patient with left temporal lobe epilepsy.

Seiichiro Saegusa; Takashi Takahashi; Junji Moriya; J Yamakawa; T Itoh; K Kusaka; Ken Kawaura; Tsugiyasu Kanda

We describe a 56-year-old woman with left temporal lobe epilepsy who developed symptoms of a panic attack. Owing to normal electroencephalography and brain magnetic resonance imaging results, she was initially diagnosed as suffering from panic attacks and treated for anxiety neurosis. The symptoms persisted and she was re-examined in our department. An interictal electroencephalogram showed paroxysmal spike waves in the left mesial temporal lobe region and this was the basis for a diagnosis of left temporal lobe epilepsy. This report suggests that left temporal lobe epilepsy should be considered as the differential diagnosis when patients frequently complain of fear or anxiety.


Immunopharmacology and Immunotoxicology | 2009

Hochu-ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not neuroprotection.

Rui Chen; Junji Moriya; Xianwen Luo; Jun-ichi Yamakawa; Takashi Takahashi; Kenroh Sasaki; Fumihiko Yoshizaki

The purpose of this study was to evaluate the beneficial effect of Hochu-ekki-to (TJ-41) combined with interferon-gamma (IFNγ) on daily activity, immunological and neurological alternation in a mouse model of chronic fatigue syndrome (CFS). CFS was induced by 6 times of repeated injection of Brucella abortus antigen every 2 weeks. Both single TJ-41 and TJ-41 combined with IFNγ increased running activity and thymus weight of CFS mice, while thicker thymic cortex together with elevation of natural killer cell activity was only found in the combined treatment group. No significant improvement was observed in the atrophic brain and decreased expression level of brain-derived neurotrophic factor and Bcl-2 mRNA in hippocampus in both treatment groups. Our results suggest that TJ-41 combined with IFNγ might have a protective effect on the marked reduction in the activity in a model of CFS via normalization of host immune responses, but not neuroprotection.

Collaboration


Dive into the Junji Moriya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jun-ichi Yamakawa

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Tsugiyasu Kanda

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

K Kusaka

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Ken Kawaura

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

J Yamakawa

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Rui Chen

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Junji Kobayashi

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Seiichiro Saegusa

Kanazawa Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge